Literature DB >> 26894506

Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival.

Scott M Glaser1, Steven F Mandish2, Beant S Gill1, Goundappa K Balasubramani3, David A Clump1, Sushil Beriwal1.   

Abstract

BACKGROUND: Anaplastic thyroid cancer (ATC) represents a rare, aggressive malignancy. We analyzed factors predictive for overall survival (OS) and treatment modality utilization.
METHODS: Using the National Cancer Data Base, we identified 3552 patients with ATC. Factors associated with surgery, high-dose radiotherapy (RT; ≥59.4 Gy), and chemotherapy utilization were evaluated using multivariable logistic regression. From this, an inverse probability-weighted propensity score was incorporated into multivariable Cox regression analyses for OS.
RESULTS: Numerous factors predictive for high-dose RT, total thyroidectomy, and chemotherapy utilization are described. Factors associated with improved survival were absence of clinical or pathologic lymph node involvement, absence of metastasis, tumor size ≤6 cm, negative surgical margins, surgery, RT, and chemotherapy. On conditional landmark analysis, improved survival seen with chemotherapy and surgery other than total thyroidectomy was lost, but persisted for total thyroidectomy and high-dose RT.
CONCLUSION: Even after correction for selection and immortal time bias, high-dose RT resulted in improved survival.
© 2016 Wiley Periodicals, Inc. Head Neck 38: E2083-E2090, 2016. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  National Cancer Data Base; anaplastic thyroid cancer; chemotherapy; patterns of care; radiotherapy; surgery

Mesh:

Year:  2016        PMID: 26894506     DOI: 10.1002/hed.24384

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  34 in total

1.  Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.

Authors:  Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2021-05-25       Impact factor: 5.344

Review 2.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

3.  Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.

Authors:  Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn
Journal:  Cancer       Date:  2016-12-27       Impact factor: 6.860

4.  Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.

Authors:  Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins
Journal:  Head Neck       Date:  2019-12-16       Impact factor: 3.147

5.  Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.

Authors:  Bin Xu; Talia Fuchs; Snjezana Dogan; Iñigo Landa; Nora Katabi; James A Fagin; R Michael Tuttle; Eric Sherman; Anthony J Gill; Ronald Ghossein
Journal:  Thyroid       Date:  2020-05-08       Impact factor: 6.568

6.  Fatal outcome of an anaplastic thyroid tumour.

Authors:  Rafael García Carretero; Cristina Peña-Arce; Gabriel Martinez-Quesada; Javier Garcia-Alvarez
Journal:  BMJ Case Rep       Date:  2017-10-25

7.  Anaplastic thyroid cancer and hyperfractionated accelerated radiotherapy (HART) with and without surgery.

Authors:  Anne-Birgitte Jacobsen; Krystyna K Grøholt; Bianca Lorntzsen; Terje A Osnes; Ragnhild Sørum Falk; Eva Sigstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-10-10       Impact factor: 2.503

8.  Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution.

Authors:  Noriyoshi Takahashi; Haruo Matsushita; Rei Umezawa; Takaya Yamamoto; Yojiro Ishikawa; Yu Katagiri; Shun Tasaka; Kazuya Takeda; Katsuya Fukui; Noriyuki Kadoya; Kengo Ito; Keiichi Jingu
Journal:  Eur Thyroid J       Date:  2018-10-04

9.  Presentation and outcomes of patients with undifferentiated thyroid carcinoma: a national perspective.

Authors:  Zaid Al-Qurayshi; Christopher Blake Sullivan; Helmi Khadra; Mohamed Shama; Grace S Lee; Emad Kandil
Journal:  Gland Surg       Date:  2021-06

Review 10.  Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.

Authors:  Ichiro Abe; Alfred King-Yin Lam
Journal:  Histol Histopathol       Date:  2020-11-10       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.